Is Exact Sciences Corporation Stock a Buy?
Owning a stock that doubles in value in less than 11 months is exciting. But what word do you use for a stock that rises to 4.5 times its original price in that amount of time? Thrilling? Exhilarating? Whatever word is the best fit, it applies to Exact Sciences (NASDAQ: EXAS).
Everything that could go right seems to be doing so for the company behind the popular Cologuard DNA screening test for colorectal cancer. But with its rapid rise leading to a very lofty valuation, is Exact Sciences stock still one for investors to buy?
Image source: Getty Images.
Source: Fool.com
Exact Sciences Aktie
60,89 €
3,06 %
Mehrere Buy-Einschätzungen geben Exact Sciences den Vorteil, ohne Sell-Einschätzungen.
Das Community-Kursziel von 76 € für Exact Sciences deutet auf eine deutliche Steigerung um mehr als 20% gegenüber dem aktuellen Kurs von 60.89 € hin.
